Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300535341> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W4300535341 endingPage "70" @default.
- W4300535341 startingPage "168" @default.
- W4300535341 abstract "(1) Platinum-based chemotherapy is generally used to treat advanced-stage non small-cell lung cancer (stages III and IV), but has only a modest impact on survival. There is no reference treatment. (2) Gefitinib inhibits the tyrosine kinase activity of the receptor for EGF (epidermal growth factor), which is thought to be involved in tumour growth. It has a temporary licence in France and is used on a named-patient basis, but full marketing authorisation has already been granted in Japan, the United States, and elsewhere. (3) Two double-blind dose-finding studies compared two doses of oral gefitinib monotherapy (250 mg/day and 500 mg/day) in patients in whom at least two lines of chemotherapy had failed. The results were favourable, with a median survival of 6 months and a symptomatic improvement in some patients, but they are undermined by the absence of a placebo group and by major protocol violations. (4) Two double-blind trials, each in more than 1000 patients, showed that gefitinib does not increase the efficacy of first-line platinum combinations. (5) About 15% of patients receiving gefitinib monotherapy in clinical trials stopped taking the treatment because of adverse events. The most frequent were gastrointestinal (diarrhea, nausea, vomiting) and cutaneous (rash, acne, dry skin, pruritus). (6) Interstitial pneumonitis occurred in about 1% of patients, and was fatal in about one-third of cases. (7) Gefitinib is metabolised by the cytochrome P450 isoenzyme CYP3A4, so carries a potentially high risk of interactions. (8) In practice, more thorough assessment of gefitinib is needed to determine whether this new drug is beneficial for patients with non small-cell lung cancer. Marketing authorisation is not currently justified." @default.
- W4300535341 created "2022-10-03" @default.
- W4300535341 date "2004-10-01" @default.
- W4300535341 modified "2023-10-18" @default.
- W4300535341 title "Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed." @default.
- W4300535341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15499696" @default.
- W4300535341 hasPublicationYear "2004" @default.
- W4300535341 type Work @default.
- W4300535341 citedByCount "0" @default.
- W4300535341 crossrefType "journal-article" @default.
- W4300535341 hasConcept C121608353 @default.
- W4300535341 hasConcept C126322002 @default.
- W4300535341 hasConcept C143998085 @default.
- W4300535341 hasConcept C197934379 @default.
- W4300535341 hasConcept C2776256026 @default.
- W4300535341 hasConcept C2776694085 @default.
- W4300535341 hasConcept C2778570526 @default.
- W4300535341 hasConcept C2779438470 @default.
- W4300535341 hasConcept C2780580376 @default.
- W4300535341 hasConcept C2780580887 @default.
- W4300535341 hasConcept C71924100 @default.
- W4300535341 hasConcept C90924648 @default.
- W4300535341 hasConceptScore W4300535341C121608353 @default.
- W4300535341 hasConceptScore W4300535341C126322002 @default.
- W4300535341 hasConceptScore W4300535341C143998085 @default.
- W4300535341 hasConceptScore W4300535341C197934379 @default.
- W4300535341 hasConceptScore W4300535341C2776256026 @default.
- W4300535341 hasConceptScore W4300535341C2776694085 @default.
- W4300535341 hasConceptScore W4300535341C2778570526 @default.
- W4300535341 hasConceptScore W4300535341C2779438470 @default.
- W4300535341 hasConceptScore W4300535341C2780580376 @default.
- W4300535341 hasConceptScore W4300535341C2780580887 @default.
- W4300535341 hasConceptScore W4300535341C71924100 @default.
- W4300535341 hasConceptScore W4300535341C90924648 @default.
- W4300535341 hasIssue "73" @default.
- W4300535341 hasLocation W43005353411 @default.
- W4300535341 hasOpenAccess W4300535341 @default.
- W4300535341 hasPrimaryLocation W43005353411 @default.
- W4300535341 hasRelatedWork W1618072806 @default.
- W4300535341 hasRelatedWork W1969875143 @default.
- W4300535341 hasRelatedWork W2015910003 @default.
- W4300535341 hasRelatedWork W2017389411 @default.
- W4300535341 hasRelatedWork W2186047679 @default.
- W4300535341 hasRelatedWork W2261901203 @default.
- W4300535341 hasRelatedWork W2358450743 @default.
- W4300535341 hasRelatedWork W2810945895 @default.
- W4300535341 hasRelatedWork W2978946191 @default.
- W4300535341 hasRelatedWork W2103674109 @default.
- W4300535341 hasVolume "13" @default.
- W4300535341 isParatext "false" @default.
- W4300535341 isRetracted "false" @default.
- W4300535341 workType "article" @default.